NEW YORK, Nov. 22, 2016 /PRNewswire/ -- Use this report to: Analyze the global market of cancer vaccines by application in various cancer types such as prostate, liver, cervical and others such as lung and urinary bladder. - Explore present and future strategies within the cancer vaccines market. - Learn about the development of the market, the holdups and the needs of the market. - Gain an insight in to the classifications and usage of the prophylactic vaccines and therapeutic vaccines. Highlights - The global market for cancer vaccines was valued at nearly $4.2 billion and $4.0 billion in 2014 and 2015, respectively. This market is expected to decline from nearly $3.5 billion in 2016 to $3.4 billion in 2021 at a compound annual growth rate (CAGR) of -0.4% for 2016-2021. - North American market is expected to grow from $1.7 billion in 2016 to nearly $1.9 billion in 2021 at a CAGR of 1.4% from 2016 through 2021. - European market is expected to grow from $777.4 million in 2016 to $847.3 million at a CAGR of 1.7% from 2016 through 2021. STUDY OBJECTIVES According to the World Health Organization, cancer has become the leading cause of death in recent years. Though cancer vaccines presently represent a minor share of the oncology industry, they are expected to be one of the most profitable segments for pharmaceutical companies over the forecast period. Most cancer vaccines work by improving a person's immune system, allowing it to attack cancer cells, and thus virus-induced cancers can be prevented using vaccines. BCC Research's goal in conducting this study is to provide an overview of the current and future dynamics of the global market for various cancer vaccines.